Dermata Therapeutics, Inc. (DRMA)
NASDAQ: DRMA · Real-Time Price · USD
1.200
+0.020 (1.69%)
At close: Jun 15, 2026, 4:00 PM EDT
1.250
+0.050 (4.17%)
After-hours: Jun 15, 2026, 7:57 PM EDT

Dermata Therapeutics Statistics

Total Valuation

DRMA has a market cap or net worth of $4.83 million. The enterprise value is -$2.12 million.

Market Cap4.83M
Enterprise Value -2.12M

Important Dates

The last earnings date was Wednesday, May 13, 2026, after market close.

Earnings Date May 13, 2026
Ex-Dividend Date n/a

Share Statistics

DRMA has 4.02 million shares outstanding. The number of shares has increased by 550.83% in one year.

Current Share Class 4.02M
Shares Outstanding 4.02M
Shares Change (YoY) +550.83%
Shares Change (QoQ) +241.28%
Owned by Insiders (%) 21.01%
Owned by Institutions (%) 5.85%
Float 3.17M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
Forward PS 48.27
PB Ratio 0.75
P/TBV Ratio 0.75
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 7.09

Current Ratio 7.09
Quick Ratio 6.60
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -103.58% and return on invested capital (ROIC) is -67.09%.

Return on Equity (ROE) -103.58%
Return on Assets (ROA) -52.66%
Return on Invested Capital (ROIC) -67.09%
Return on Capital Employed (ROCE) -114.77%
Weighted Average Cost of Capital (WACC) 8.04%
Revenue Per Employee n/a
Profits Per Employee -$789,186
Employee Count9
Asset Turnover n/a
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -83.15% in the last 52 weeks. The beta is 0.69, so DRMA's price volatility has been lower than the market average.

Beta (5Y) 0.69
52-Week Price Change -83.15%
50-Day Moving Average 1.26
200-Day Moving Average 2.51
Relative Strength Index (RSI) 45.24
Average Volume (20 Days) 52,107

Short Selling Information

The latest short interest is 96,498, so 2.40% of the outstanding shares have been sold short.

Short Interest 96,498
Short Previous Month 114,588
Short % of Shares Out 2.40%
Short % of Float 3.05%
Short Ratio (days to cover) 1.84

Income Statement

Revenue n/a
Gross Profit n/a
Operating Income -7.36M
Pretax Income -7.10M
Net Income -7.10M
EBITDA n/a
EBIT -7.36M
Earnings Per Share (EPS) -$4.03
Full Income Statement

Balance Sheet

The company has $6.95 million in cash and n/a in debt, with a net cash position of $6.95 million or $1.73 per share.

Cash & Cash Equivalents 6.95M
Total Debt n/a
Net Cash 6.95M
Net Cash Per Share $1.73
Equity (Book Value) 6.41M
Book Value Per Share 1.59
Working Capital 6.41M
Full Balance Sheet

Cash Flow

Operating Cash Flow -8.30M
Capital Expenditures n/a
Depreciation & Amortization n/a
Net Borrowing n/a
Free Cash Flow n/a
FCF Per Share n/a
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

DRMA does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -550.83%
Shareholder Yield -550.83%
Earnings Yield -147.16%
FCF Yield n/a

Analyst Forecast

The average price target for DRMA is $4.00, which is 233.33% higher than the current price. The consensus rating is "Buy".

Price Target $4.00
Price Target Difference 233.33%
Analyst Consensus Buy
Analyst Count 1
Revenue Growth Forecast (3Y) n/a
EPS Growth Forecast (3Y) n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

The last stock split was on August 1, 2025. It was a reverse split with a ratio of 1:10.

Last Split Date Aug 1, 2025
Split Type Reverse
Split Ratio 1:10

Scores

Altman Z-Score n/a
Piotroski F-Score 1